Monday, June 21
Shadow

Its about trust: UNMC physician weighs in on Pfizers COVID-19 vaccine – KETV Omaha

There’s a light at the end of the COVID-19 tunnel with a vaccine on the way, but UNMC’s Dr. Ali Khan says there’s still a long way to go. Monday, pharmaceutical giant Pfizer announced its current vaccine is 90% effective. “This isn’t just about safety and efficacy,” said Khan. “It’s about trust and there’s a whole process to ensure trust, so when you get it a lot of independent people have seen this vaccine and say, ‘Yes, it’s good'”The vaccine still faces layers of approval from Pfizer’s external review board, to the Food and Drug Administration and Centers for Disease Control and Prevention.Khan said the vaccine could officials be approved by December and health care workers will be first in line to receive it. “Without a doubt, the first group is the health care workers because they have the most intense exposure of anybody else,” said Khan. “Then the second group very quickly becomes these high-risk people, for example in long-term care facilities.”Pfizer said it got the 90% effective rate by looking at 94 infections, studying nearly 44,000 people. Khan explained the vaccination will be two doses, about 21 days apart. The doctor explained the vaccination likely won’t be widely available until the spring. “Everybody is not going to be vaccinated in the U.S., so vaccines will be one more layer of protection,” said Khan. “It’s not as if all of a sudden we’ll stop doing everything, It’s just going to be one more layer of protections until we truly get cases down in our community.”

There’s a light at the end of the COVID-19 tunnel with a vaccine on the way, but UNMC’s Dr. Ali Khan says there’s still a long way to go. Monday, pharmaceutical giant Pfizer announced its current vaccine is 90% effective.

“This isn’t just about safety and efficacy,” said Khan. “It’s about trust and there’s a whole process to ensure trust, so when you get it [the vaccine] a lot of independent people have seen this vaccine and say, ‘Yes, it’s good'”

The vaccine still faces layers of approval from Pfizer’s external review board, to the Food and Drug Administration and Centers for Disease Control and Prevention.

Khan said the vaccine could officials be approved by December and health care workers will be first in line to receive it.

“Without a doubt, the first group is the health care workers because they have the most intense exposure of anybody else,” said Khan. “Then the second group very quickly becomes these high-risk people, for example in long-term care facilities.”

Pfizer said it got the 90% effective rate by looking at 94 infections, studying nearly 44,000 people.

Khan explained the vaccination will be two doses, about 21 days apart. The doctor explained the vaccination likely won’t be widely available until the spring.

“Everybody is not going to be vaccinated in the U.S., so vaccines will be one more layer of protection,” said Khan. “It’s not as if all of a sudden we’ll stop doing everything, It’s just going to be one more layer of protections until we truly get cases down in our community.”

Leave a Reply

Your email address will not be published. Required fields are marked *